Skip to main content
Premium Trial:

Request an Annual Quote

Mediomics Lands $1M SBIR Award for Biologic Analysis Tool

NEW YORK (GenomeWeb News) – Mediomics has reeled in a $997,251 grant from the National Cancer Institute to continue developing technologies for monitoring the titer and quality of recombinant biologics, the company said today.

The phase II Small Business Innovation Research grant will fund efforts to develop an automated in-process analyzer using the company's Pincer platform, including development of quantitative antigen-specific assays for antibody titer, affinity, glycosylation, and aggregation. The firm expects that the analyzer will be beta-tested by Gallus Pharmaceuticals, a biologics manufacturer.

The St. Louis-based firm is focused on developing assay kits, biosensors, and microarrays for academic and corporate research, point-of-care testing, and food and pharmaceutical production control. These kits will quantify a range of macromolecules including ligands, proteins, protein complexes, and pathogens, such as bacteria, fungi, and viruses.

"The grant will be extremely helpful to move this cheaper, faster screening technology into mainstream applications," Mediomics President Yie-Hwa Chang said in a statement.

Chang said that the PINCER-based analyzer "will displace cumbersome benchtop instruments and gain acceptance for use in biologics production and food pathogen detection."

Mediomics has licensed its core technologies exclusively from Saint Louis University, including the molecular Pincer-based homogeneous biosensor and bioassay platforms and devices, the Bridge-It DNA-binding protein-based bioassay, and methods for screening and developing new high-affinity capture reagents for research, diagnostic, and therapeutic use.

The company also said it will continue to collaborate with Daren Chen, a professor of engineering at Washington University, on the design of an automated stand-alone detection tool.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.